Nippon India Nifty Pharma ETF-Growth
Equity: Sectoral-Pharma - Growth (Open ended)
SEBI Riskometer: Very HighCategory: Equity: Sectoral-PharmaBenchmark: NIFTY Pharma Total Return IndexCheck Portfolio Overlap →
₹27.5+0.49%
18 Sept 2026
Holdings Analysis
ETF constituent allocation snapshot — equity, sector concentration and market cap distribution for Nippon India Nifty Pharma ETF-Growth.
Market Cap Distribution
Large Cap (47.8%)
Mid Cap (45.1%)
Small Cap (7.1%)
Historical Asset Allocation
| Asset | 31 Aug 2026 | 31 Jul 2026 | 30 Jun 2026 | 31 May 2026 | 30 Apr 2026 | 31 Mar 2026 |
|---|---|---|---|---|---|---|
| Equity | 99.95% | 99.78% | 99.90% | 99.95% | 99.98% | 99.97% |
| Debt | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Others (incl. cash) | 0.05% | 0.22% | 0.10% | 0.05% | 0.02% | 0.03% |
| Commodities | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Real Estate | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Portfolio Snapshot
No. of Securities
21
P/E Ratio
39.69
P/B Ratio
5.05
Top Holding %
20.75%
Top 5 Holdings %
55.16%
Top 10 Holdings %
78.82%
AUM
₹1,761 Cr
Expense Ratio
0.23%
Since Inception
12.97%
Max Drawdown
-0.21%
Alpha
-0.06%
Sharpe Ratio
0.98
Top Portfolio Holdings by Weight
Latest portfolio holdings sorted by allocation weight. Includes instrument name, sector, number of shares, market value (₹ Cr) and percentage of net assets. Switch dates or categories using the controls below.
| Instrument | Sector | No. of Shares | Value (Rs. Cr) | Weight | Change |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | Healthcare | 18,40,784 | 365.36 | 20.75% | -0.54%↓ |
| Divis Laboratories Ltd. | Healthcare | 2,20,941 | 209.16 | 11.88% | 1.54%↑ |
| Cipla Ltd. | Healthcare | 9,78,190 | 137.85 | 7.83% | -0.54%↓ |
| Laurus Labs Ltd. | Healthcare | 6,76,401 | 129.53 | 7.36% | 0.22%↑ |
| Torrent Pharmaceuticals Ltd. | Healthcare | 2,54,999 | 129.18 | 7.34% | -0.25%↓ |
| Dr. Reddys Laboratories Ltd. | Healthcare | 10,59,711 | 122.33 | 6.95% | -0.12%↓ |
| Lupin Ltd. | Healthcare | 4,22,174 | 92.39 | 5.25% | -0.68%↓ |
| Aurobindo Pharma Ltd. | Healthcare | 4,81,186 | 82.62 | 4.69% | 0.27%↑ |
| Glenmark Pharmaceuticals Ltd. | Healthcare | 2,61,749 | 64.91 | 3.69% | 0.29%↑ |
| Alkem Laboratories Ltd. | Healthcare | 1,01,737 | 54.22 | 3.08% | -0.32%↓ |
| Biocon Ltd. | Healthcare | 12,40,315 | 51.1 | 2.90% | -0.17%↓ |
| Zydus Lifesciences Ltd. | Healthcare | 4,34,941 | 50.51 | 2.87% | 0.02%↑ |
| Ipca Laboratories Ltd. | Healthcare | 2,41,488 | 47.69 | 2.71% | 0.26%↑ |
| Mankind Pharma Ltd. | Healthcare | 1,96,801 | 47.61 | 2.70% | -0.12%↓ |
| Gland Pharma Ltd. | Healthcare | 1,38,524 | 39.98 | 2.27% | 0.25%↑ |
| Sai Life Sciences Ltd. | Healthcare | 2,39,870 | 35.01 | 1.99% | 0.16%↑ |
| Wockhardt Ltd. | Healthcare | 1,43,561 | 27.04 | 1.54% | -0.09%↓ |
| Ajanta Pharma Ltd. | Healthcare | 73,229 | 26.38 | 1.50% | 0.03%↑ |
| Abbott India Ltd. | Healthcare | 9,055 | 23.41 | 1.33% | -0.13%↓ |
| Piramal Pharma Ltd. | Healthcare | 10,81,282 | 23.18 | 1.32% | 0.09%↑ |
Sector-wise Portfolio Allocation
Equity exposure by sector as a percentage of total net assets, tracked across recent portfolio dates. Identifies concentration risk and sector rotation trends in the fund's holdings.
| Sector | 31 Aug 2026 | 31 Jul 2026 | 30 Jun 2026 | 31 May 2026 | 30 Apr 2026 | 31 Mar 2026 |
|---|---|---|---|---|---|---|
| Healthcare | 99.95% | 99.78% | 99.90% | 99.95% | 99.98% | 99.97% |
Equity Insights
A detailed look at the equity holdings of this scheme — aggregated scores on value, momentum, quality parameters along with diversification and performance analysis.
Style Analysis
Value score
34.4 / 100
Weighted average Value score is 34.4. This indicates that portfolio is relatively reasonably valued using composite of value measures.
Price Momentum score
70.2 / 100
Weighted average Price Momentum score is 70.2. This indicates that portfolio has average momentum using composite of momentum measures.
Quality score
84.8 / 100
Weighted average Quality score is 84.8. This indicates that portfolio has high quality using composite of quality measures.
QVM score
76.0 / 100
Weighted average QVM score is 76.0. This indicates that portfolio has high QVM score and hence could be considered for investment.
Red Flags
Frequently Asked Questions
What are the top holdings of Nippon India Nifty Pharma ETF-Growth?
The top holdings of Nippon India Nifty Pharma ETF-Growth as of 31 Aug 2026 are Sun Pharmaceutical Industries Ltd. (20.75%), Divis Laboratories Ltd. (11.88%), Cipla Ltd. (7.83%), Laurus Labs Ltd. (7.36%), Torrent Pharmaceuticals Ltd. (7.34%). These top 5 stocks together account for 55.16% of the total portfolio. You can view the complete holdings breakdown above.
How many stocks does Nippon India Nifty Pharma ETF-Growth hold in its portfolio?
Nippon India Nifty Pharma ETF-Growth holds 21 stocks in its portfolio as of 31 Aug 2026. The fund's portfolio size reflects the fund manager's investment approach, a more concentrated portfolio indicates higher conviction bets, while a larger number of holdings suggests a more diversified strategy.
What is the sector allocation of Nippon India Nifty Pharma ETF-Growth?
As of 31 Aug 2026, Nippon India Nifty Pharma ETF-Growth's top sector allocations are Healthcare (99.95%). You can find detailed sector allocation above.
What is the equity and debt allocation of Nippon India Nifty Pharma ETF-Growth?
As of 31 Aug 2026, Nippon India Nifty Pharma ETF-Growth has 99.95% allocated to equity, and 0.00% to debt. You can also check the historical trends above.
What is the market cap allocation of Nippon India Nifty Pharma ETF-Growth?
As of 31 Aug 2026, Nippon India Nifty Pharma ETF-Growth's market cap allocation is 47.82% in large caps, 45.05% in mid caps, and 7.12% in small caps.
What is the PE ratio of Nippon India Nifty Pharma ETF-Growth's portfolio?
The portfolio PE ratio of Nippon India Nifty Pharma ETF-Growth is 39.69 as of 31 Aug 2026. The portfolio PE ratio tells you how expensive or cheap the fund's holdings are relative to their earnings.
What is the credit quality of Nippon India Nifty Pharma ETF-Growth?
A credit rating breakdown is not available for Nippon India Nifty Pharma ETF-Growth — its non-equity allocation was 0.00% as of the latest disclosure. This is common when a fund's non-equity holdings are mostly cash or short-term money market instruments, which aren't assigned a credit rating the way bonds are.
When is the latest portfolio disclosure for Nippon India Nifty Pharma ETF-Growth?
The latest portfolio disclosure for Nippon India Nifty Pharma ETF-Growth is as of 31 Aug 2026. SEBI requires all mutual funds to disclose their complete portfolio holdings on a monthly basis, typically within 10 days of the end of each month.